Business Wire

Phones, Payments and the Pandemic: Covid’s Impact on How We Communicate and Spend Money

Share

The release of the Inaugural Ding Global Prepaid Index (GPI) has produced unexpected findings of an untapped market with high growth potential that has been accelerated by the Covid-19 pandemic. This bi-annual global study commissioned by Ding, the world’s largest mobile top-up service, examines the views of 7,000 respondents across the US, the UK, France, KSA, UAE, Qatar, Brazil, Indonesia, and the Philippines, regarding their engagement in the prepaid market and their attitudes towards it. The prepaid market is defined as people who use prepaid mobile billing; prepaid financial products such as prepaid credit cards; prepaid utility bill payment, or prepaid gift cards / vouchers.

Market Intelligence - what the report tells us

This report is telling: 79% of respondents use at least one prepaid service, while 45% use two or more; prepay is seen as a more flexible way to engage the services they need and want rather than bill pay (or postpay) options. Prepaid mobile bills account for the highest usage (61%), followed by prepaid utility bills (31%), prepaid vouchers and gift cards (19%) and prepaid financial products such as a prepaid visa card (17%).

While many assume that the prepaid market primarily serves those in a lower income bracket, the study has revealed that a high number across all income brackets engage in prepaid services. In fact, higher-income earners use prepaid products most, with 84% of respondents in this bracket stating they use prepaid services. This result is relatively high across the board, with 78% of low-income earners using prepaid services as do 79% of medium-income earners.

“The Global Prepaid Index has revealed the enormous market potential for prepaid products,” said Mark Roden, Chief Executive and Founder of Ding. “Our research shows that prepaid products attract all walks of life, with many people engaging by choice rather than out of necessity. In an era where we can use technology to provide better transparency and control over our finances, as well as to use it to quickly access services, it is no surprise that people are willing to have their electricity or mobile phone service cut off for example because, in minutes, they can just top it up again.”

Market Opportunity

“Today we see a business opportunity to cater to the prepaid market more than ever,” said Roden. “The Covid-19 pandemic has accelerated this trend not only due to financial uncertainty but also with many unable to see their loved ones in person due to social distancing and restrictions on international travel. Even on our own platform, we have seen close to a 50% annual uptick in prepaid transactions during 2020, with customers prioritising keeping in contact by either topping up their own phones or sending airtime to others.”

*** Ends ***

About the Ding Global Prepaid Index (GPI)

The Ding Global Prepaid Index (GPI) is a major bi-annual survey analysing the prepaid market.

The inaugural GPI shines a light on the people who may see prepaid products and services as their only option to live in the world today. 7,000 respondents were surveyed across Europe, Asia and the Americas regarding their use of prepaid offerings, examining the attitudes, activities and outlook of the forgotten billion in particular during the Covid-19 pandemic.

Those surveyed were evenly distributed across gender and aged over 18, 30 percent of the sample also identified as expats.

About Ding

Ding was founded to improve people’s lives by helping those with less gain access to more. As the number one international mobile top-up service in the world, Ding has been keeping people connected since 2006, when it launched this first-of-a-kind service. Today, Ding’s users have successfully sent over 450 million top-ups globally, via the app, online at Ding.com, and in-store at over 600,000+ retail outlets worldwide.

Ding is the world’s leading universal top-up service. Ding delivers a top-up every second, via 550+ operators, across 140+ countries – helping families and friends around the world to stay connected.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information:
Bianca Delbao
CW8 Communications
ding@cw8-communications.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye